RxDoctor Payments Data

Vamsee Lakkakula, MD

Cardiovascular Disease · Chesapeake, VANPI 1902283013

Payments from drug & device makers

$8,226in general payments, 2019–2025

Across 271 payments — averaging $30.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$2K
  • Biotronik Inc.$1K
  • E.r. Squibb & Sons, L.L.C.$520
  • Amgen$496
  • Esperion Therapeutics, Inc.$411
  • Boehringer Ingelheim$366
  • plus $4K from 28 others

What the payments were for

  • Travel & lodging$3364%
  • Food & beverage$7,88996%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,226 in reported general payments places this provider in the 75th percentile of 548 cardiovascular disease providers in Virginia.

See all cardiovascular disease providers in Virginia

Medicare billing

Part B allowed, 2024
$138,426
Medicare patients
583
Services billed
1,826

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban231$231,429
EntrestoSacubitril/Valsartan62$67,680
JardianceEmpagliflozin49$65,767
XareltoRivaroxaban31$35,837
Repatha SureclickEvolocumab51$32,636
FarxigaDapagliflozin Propanediol23$21,628
NexlizetBempedoic Acid/Ezetimibe15$9,671
BrilintaTicagrelor13$9,171
Metoprolol Succinate366$6,099
Rosuvastatin Calcium265$3,459
Atorvastatin Calcium136$2,072
Bumetanide22$907
Torsemide41$862
Losartan Potassium53$763
Amlodipine Besylate90$698

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$228$231,429231 claims
NovartisEntresto$232$67,68062 claims
Boehringer IngelheimJardiance$366$65,76749 claims
Johnson & JohnsonXarelto$139$35,83731 claims
Esperion Therapeutics, Inc.Nexlizet$411$9,67115 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 548 cardiovascular disease providers in Virginia.

Other cardiovascular disease in Chesapeake

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →